Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 19/20 | 0.74 |
| ▸ | MAOB | P27338 | 19/20 | 0.74 |
| ▸ | IDO1 | P14902 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17144586 | 0.85 | MAOA (1.00) | MAOAMAOB | |
| Bromide SCHEMBL29420161 | 0.84 | MAOA (0.97) | MAOAMAOB | |
| SCHEMBL17150990 | 0.84 | MAOA (1.00) | MAOAMAOB | |
| SCHEMBL17144293 | 0.82 | MAOB (0.73) | MAOAMAOB | |
| SCHEMBL18998987 | 0.81 | MAOA (1.00) | MAOAMAOB | |
| SCHEMBL17150995 | 0.80 | MAOA (0.73) | MAOAMAOB | |
| SCHEMBL19017688 | 0.80 | MAOA (1.00) | MAOAMAOB | |
| SCHEMBL30118286 | 0.77 | MEN1 (0.59) | IDO1 | |
| SCHEMBL28911583 | 0.77 | MEN1 (0.59) | IDO1 | |
| SCHEMBL17144588 | 0.77 | MAOA (1.00) | MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106794125-B | NAT10 modulators for the treatment or prevention of laminopathies, aging and cancer | 剑桥企业有限公司 | 2021-11-23 | — | — | CN | claimed |
| US-9809562-B2 | NAT10 modulators for treating or preventing laminopathies, aging and cancer | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2017-11-07 | — | — | US | disclosed |
| US-9809562-B2 | NAT10 modulators for treating or preventing laminopathies, aging and cancer | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2017-11-07 | — | — | US | disclosed |
| US-9809562-B2 | NAT10 modulators for treating or preventing laminopathies, aging and cancer | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2017-11-07 | — | — | US | disclosed |
| US-20170174644-A1 | NAT10 MODULATORS FOR TREATING OR PREVENTING LAMINOPATHIES, AGING AND CANCER | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2017-06-22 | — | — | US | disclosed |
| US-20170174644-A1 | NAT10 MODULATORS FOR TREATING OR PREVENTING LAMINOPATHIES, AGING AND CANCER | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2017-06-22 | — | — | US | disclosed |
| US-20170174644-A1 | NAT10 MODULATORS FOR TREATING OR PREVENTING LAMINOPATHIES, AGING AND CANCER | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2017-06-22 | — | — | US | disclosed |
| WO-2015150824-A1 | NAT10 MODULATORS FOR TREATING OR PREVENTING LAMINOPATHIES, AGING AND CANCER | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2015-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174644-A1 | NAT10 MODULATORS FOR TREATING OR PREVENTING LAMINOPATHIES, AGING AND CANCER | LMNB2, LMNB1, LMNA | MAOA 4114/4885MAOB 4229/4885IDO1 4713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.